Citadel Advisors’s Arcadia Biosciences RKDA Stock Holding History

Citadel Advisors’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,536	Closed	-$49.2K	–	15391
2022 Q4	$49.2K	Buy	+4,536	New	+$64.6K	﹤0.01%	12165
2022 Q3	–	Sell	-1,428	Closed	-$48.7K	–	13460
2022 Q2	$58K	Buy	1,428 +577	+68%	+$26.5K	﹤0.01%	11843
2022 Q1	$48K	Sell	851 -766	-47%	-$36.5K	﹤0.01%	12818
2021 Q4	$67K	Buy	+1,617	New	+$105K	﹤0.01%	13070
2020 Q2	–	Sell	-286	Closed	-$33K	–	10393
2020 Q1	$33K	Buy	+286	New	+$49.8K	﹤0.01%	9172
2019 Q4	–	Sell	-414	Closed	-$77K	–	9656
2019 Q3	$77K	Buy	414 +151	+57%	+$29K	﹤0.01%	8585
2019 Q2	$32K	Buy	+263	New	+$55.9K	﹤0.01%	8857
2017 Q2	–	Sell	-35	Closed	-$19K	–	7963
2017 Q1	$19K	Buy	+35	New	+$25.1K	﹤0.01%	7258
2016 Q4	–	Sell	-13	Closed	-$19K	–	7750
2016 Q3	$19K	Buy	+13	New	+$23K	﹤0.01%	7070

Other funds holding RKDA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's RKDA Position: Q1 2023 in Review

Citadel Advisors sold out of Arcadia Biosciences (RKDA) in Q1 2023, closing a stake of 4,536 shares — an estimated $49.2K sold.

Citadel Advisors first reported a position in RKDA in Q3 2016 and held it in 9 quarters. The position peaked at $77K in Q3 2019. 15 funds tracked by Wall St. Rank hold RKDA as of Q1 2023.

Citadel Advisors reported no remaining Arcadia Biosciences position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 4,536 Arcadia Biosciences shares in Q1 2023, an estimated $49.2K.
Citadel Advisors first reported a position in Arcadia Biosciences in Q3 2016 and held it in 9 quarters.
Citadel Advisors's Arcadia Biosciences position peaked at $77K in Q3 2019.
15 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.